Department of Nuclear Medicine and Centre for PET, Austin Health, VIC, Australia; Department of Medicine, The University of Melbourne, Austin Health, VIC, Australia; The Florey Institute, The University of Melbourne, Victoria, Australia.
Department of Nuclear Medicine and Centre for PET, Austin Health, VIC, Australia; The Florey Institute, The University of Melbourne, Victoria, Australia.
Lancet Neurol. 2015 Jan;14(1):114-24. doi: 10.1016/S1474-4422(14)70252-2.
Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation in the brain, facilitating research into causes, diagnosis, and treatment of major tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. Neuropathological studies of Alzheimer's disease show a strong association between tau deposits, decreased cognitive function, and neurodegenerative changes. Selective tau imaging will allow the in-vivo exploration of such associations and measure the global and regional changes in tau deposits over time. Such imaging studies will comprise non-invasive assessment of the spatial and temporal pattern of tau deposition over time, providing insight into the role tau plays in ageing and helping to establish the relation between cognition, genotype, neurodegeneration, and other biomarkers. Once validated, selective tau imaging might be useful as a diagnostic, prognostic, and progression biomarker, and a surrogate marker for the monitoring of efficacy and patient recruitment for anti-tau therapeutic trials.
使用选择性的活体 tau 成像将有助于更好地了解脑内 tau 聚集，从而促进对主要 tau 病（如阿尔茨海默病、进行性核上性麻痹、皮质基底节综合征、慢性创伤性脑病和一些额颞叶变性变体）的病因、诊断和治疗的研究。阿尔茨海默病的神经病理学研究表明 tau 沉积物与认知功能下降和神经退行性变化之间存在很强的关联。选择性 tau 成像将允许在体内探索这种关联，并测量 tau 沉积物随时间的全局和区域变化。这些成像研究将包括对 tau 沉积的时空模式进行非侵入性评估，深入了解 tau 在衰老中的作用，并有助于建立认知、基因型、神经退行性变和其他生物标志物之间的关系。一旦得到验证，选择性 tau 成像可能作为一种诊断、预后和进展的生物标志物，以及用于监测抗 tau 治疗试验的疗效和患者招募的替代标志物。
